Crosstalk between reverse cholesterol transport and innate immunity

Trends in Endocrinology and Metabolism

Volumn 23, Issue 4, 2012, Pages 169-178

  Azzam, Kathleen M ^a   Fessler, Michael B ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; CHOLESTEROL; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; LIPOTEICHOIC ACID; LIVER TRIACYLGLYCEROL LIPASE; LIVER X RECEPTOR AGONIST; MYELOID DIFFERENTIATION FACTOR 88; MYELOPEROXIDASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID TRANSFER PROTEIN; PROTEIN TYROSINE KINASE; SCAVENGER RECEPTOR B; SERUM AMYLOID A; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; VERY LOW DENSITY LIPOPROTEIN;

ATHEROMA; ATHEROSCLEROSIS; AUTOPHAGY; CHOLESTEROL TRANSPORT; ENDOPLASMIC RETICULUM STRESS; ENDOTOXEMIA; HYDROLYSIS; IMMUNE RESPONSE; IN VIVO STUDY; INFLUENZA A; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE INFECTION; LIPID METABOLISM; LIPID TRANSPORT; LISTERIOSIS; LUNG INFECTION; METABOLIC SYNDROME X; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; REVIEW; SEPSIS; TUBERCULOSIS;

EID: 84858753720     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.02.001     Document Type: Review

References (100)

1. Yin K., et al. ATP-binding membrane cassette transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. Mol. Med. 2010, 16:438-449.
2. Kellner-Weibel G., de la Llera-Moya M. Update on HDL receptors and cellular cholesterol transport. Curr. Atheroscler. Rep. 2011, 13:233-241.
3. Temel R.E., Brown J.M. A new framework for reverse cholesterol transport: non-biliary contributions to reverse cholesterol transport. World J. Gastroenterol. 2010, 16:5946-5952.
4. Yasuda T., et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler. Thromb. Vasc. Biol. 2010, 30:781-786.
5. Tellier E., et al. HDLs activate ADAM17-dependent shedding. J. Cell. Physiol. 2008, 214:687-693.
6. van der Velde A.E., et al. Transintestinal cholesterol efflux. Curr. Opin. Lipidol. 2010, 21:167-171.
7. Nijstad N., et al. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology 2011, 140:1043-1051.
8. Xie C., et al. ABCA1 plays no role in the centripetal movement of cholesterol from peripheral tissues to the liver and intestine in the mouse. J. Lipid Res. 2009, 50:1316-1329.
9. Zanotti I., et al. Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo. Arterioscler. Thromb. Vasc. Biol. 2011, 31:74-80.
10. Tanigawa H., et al. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation 2009, 120:160-169.
11. Annema W., Tietge U.J. Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Curr. Atheroscler Rep. 2011, 13:257-265.
12. Yazdanyar A., et al. Role of phospholipid transfer protein in high-density lipoprotein-mediated reverse cholesterol transport. Curr. Atheroscler. Rep. 2011, 13:242-248.
13. Ouimet M., et al. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab. 2011, 13:655-667.
14. Moore K.J., et al. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu. Rev. Nutr. 2011, 31:49-63.
15. Kirschning C.J., et al. Similar organization of the lipopolysaccharide-binding protein (LBP) and phospholipid transfer protein (PLTP) genes suggests a common gene family of lipid-binding proteins. Genomics 1997, 46:416-425.
16. Levels J.H., et al. Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect. Immun. 2005, 73:2321-2326.
17. Kitchens R.L., et al. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J. Biol. Chem. 1999, 274:34116-34122.
18. Thompson P.A., et al. Apolipoprotein A-II augments monocyte responses to LPS by suppressing the inhibitory activity of LPS-binding protein. Innate Immun. 2008, 14:365-374.
19. Vishnyakova T.G., et al. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J. Biol. Chem. 2003, 278:22771-22780.
20. Thompson P.A., et al. ABCA1 promotes the efflux of bacterial LPS from macrophages and accelerates recovery from LPS-induced tolerance. J. Lipid Res. 2010, 51:2672-2685.
21. Gautier T., Lagrost L. Plasma PLTP (phospholipid-transfer protein): an emerging role in 'reverse lipopolysaccharide transport' and innate immunity. Biochem. Soc. Trans. 2011, 39:984-988.
22. Annema W., et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J. Lipid Res. 2010, 51:743-754.
23. Malik P., et al. Zymosan-mediated inflammation impairs in vivo reverse cholesterol transport. J. Lipid Res. 2011, 52:951-957.
24. McGillicuddy F.C., et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009, 119:1135-1145.
25. Tietge U.J., et al. Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA2. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E403-E411.
26. Castrillo A., et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 2003, 12:805-816.
27. Khovidhunkit W., et al. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J. Lipid Res. 2003, 44:1728-1736.
28. Khovidhunkit W., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 2004, 45:1169-1196.
29. Li Y., et al. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and MAP kinase-dependent inflammation in advanced atherosclerosis. J. Biol. Chem. 2005, 280:21763-21772.
30. Frisdal E., et al. Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response. J. Biol. Chem. 2011, 286:30926-30936.
31. Gerbod-Giannone M.C., et al. TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:3112-3117.
32. Kaplan R., et al. Bacterial lipopolysaccharide induces expression of ABCA1 but not ABCG1 via an LXR-independent pathway. J. Lipid Res. 2002, 43:952-959.
33. Smoak K.A., et al. Myeloid differentiation primary response protein 88 couples reverse cholesterol transport to inflammation. Cell Metab. 2010, 11:493-502.
34. Smith J.D. Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. J. Clin. Lipidol. 2010, 4:382-388.
35. G H.B., et al. Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response. Cholesterol 2011, 2011:274629.
36. Jahangiri A., et al. HDL remodeling during the acute phase response. Arterioscler. Thromb. Vasc. Biol. 2009, 29:261-267.
37. de Beer M.C., et al. ATP binding cassette G1-dependent cholesterol efflux during inflammation. J. Lipid Res. 2011, 52:345-353.
38. Wroblewski J.M., et al. Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase. J. Lipid Res. 2011, 52:2255-2261.
39. van der Westhuyzen D.R., et al. Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I. J. Biol. Chem. 2005, 280:35890-35895.
40. Undurti A., et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 2009, 284:30825-30835.
41. Shao B., Heinecke J.W. Impact of HDL oxidation by the myeloperoxidase system on sterol efflux by the ABCA1 pathway. J. Proteomics 2011, 74:2289-2299.
42. Wu Z., et al. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat. Struct. Mol. Biol. 2007, 14:861-868.
43. Sun Y., et al. Free cholesterol accumulation in macrophage membranes activates Toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ. Res. 2009, 104:455-465.
44. Suzuki M., et al. Endosomal accumulation of Toll-like receptor 4 causes constitutive secretion of cytokines and activation of signal transducers and activators of transcription in Niemann-Pick disease type C (NPC) fibroblasts: a potential basis for glial cell activation in the NPC brain. J. Neurosci. 2007, 27:1879-1891.
45. Suzuki M., et al. High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation 2010, 122:1919-1927.
46. Duewell P., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
47. Koseki M., et al. Increased lipid rafts and accelerated lipopolysaccharide-induced tumor necrosis factor-α secretion in Abca1-deficient macrophages. J. Lipid Res. 2007, 48:299-306.
48. Zhu X., et al. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J. Lipid Res. 2010, 51:3196-3206.
49. Tang C., et al. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J. Biol. Chem. 2009, 284:32336-32343.
50. Yvan-Charvet L., et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2008, 118:1837-1847.
51. Yvan-Charvet L., et al. ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ. Res. 2010, 106:1861-1869.
52. Draper D.W., et al. ATP-binding cassette transporter G1 deficiency dysregulates host defense in the lung. Am. J. Respir. Crit. Care Med. 2010, 182:404-412.
53. Calkin A.C., Tontonoz P. Liver X receptor signaling pathways and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1513-1518.
54. Joseph S.B., et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 2003, 9:213-219.
55. Smoak K., et al. Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J. Immunol. 2008, 180:3305-3312.
56. Pommier A.J., et al. Liver X receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene 2010, 29:2712-2723.
57. Ghisletti S., et al. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 2009, 23:681-693.
58. Ghisletti S., et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol. Cell 2007, 25:57-70.
59. A-Gonzalez N., et al. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009, 31:245-258.
60. Korf H., et al. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J. Clin. Investig. 2009, 119:1626-1637.
61. Joseph S.B., et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 2004, 119:299-309.
62. Fontaine C., et al. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ. Res. 2007, 101:40-49.
63. Torocsik D., et al. Activation of liver X receptor sensitizes human dendritic cells to inflammatory stimuli. J. Immunol. 2010, 184:5456-5465.
64. Bauman D.R., et al. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:16764-16769.
65. Guo L., et al. Scavenger receptor BI protects against septic death through its role in modulating inflammatory response. J. Biol. Chem. 2009, 284:19826-19834.
66. Vishnyakova T.G., et al. CLA-1 and its splicing variant CLA-2 mediate bacterial adhesion and cytosolic bacterial invasion in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16888-16893.
67. Cai L., et al. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J. Clin Investig. 2008, 118:364-375.
68. Cazita P.M., et al. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock 2008, 30:590-595.
69. Hara T., et al. Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both in vitro and in vivo. J. Lipid Res. 2011, 52:57-67.
70. Pays E., Vanhollebeke B. Human innate immunity against African trypanosomes. Curr. Opin. Immunol. 2009, 21:493-498.
71. Thomson R., et al. Activity of trypanosome lytic factor: a novel component of innate immunity. Future Microbiol. 2009, 4:789-796.
72. Samanovic M., et al. Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates Leishmania infection. PLoS Pathog. 2009, 5:e1000276.
73. Murphy A.J., et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2071-2077.
74. Murphy A.J., et al. Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim. Biophys. Acta 2011, 10.1016/j.bbalip.2011.08.003.
75. Kawakami A., et al. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ. Res. 2008, 103:1402-1409.
76. Yin K., et al. Tristetraprolin-dependent post-transcriptional regulation of inflammatory cytokine mRNA expression by apolipoprotein A-I: role of ATP-binding membrane cassette transporter A1 and signal transducer and activator of transcription 3. J. Biol. Chem. 2011, 286:13834-13845.
77. Wilhelm A.J., et al. Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler. Thromb. Vasc. Biol. 2009, 29:843-849.
78. -/- mice. J. Biol. Chem. 2010, 285:36158-36169.
79. Bjorkbacka H., et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 2004, 10:416-421.
80. Degoma E.M., Rader D.J. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol. 2011, 8:266-277.
81. Navab M., et al. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 2011, 8:222-232.
82. Zhang Z., et al. Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H866-H873.
83. Dai L., et al. The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic rats. J. Lipid Res. 2010, 51:2695-2705.
84. Van Lenten B.J., et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation 2004, 110:3252-3258.
85. Nandedkar S.D., et al. D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J. Lipid Res. 2011, 52:499-508.
86. Amar J., et al. Energy intake is associated with endotoxemia in apparently healthy men. Am. J. Clin. Nutr. 2008, 87:1219-1223.
87. Vijay-Kumar M., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
88. Bae Y.S., et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ. Res. 2009, 104:210-218.
89. Blanc M., et al. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol. 2011, 9:e1000598.
90. Schmitz G., Orso E. CD14 signalling in lipid rafts: new ligands and co-receptors. Curr. Opin. Lipidol. 2002, 13:513-521.
91. Poltorak A., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
92. Yu B., et al. Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J. Clin. Investig. 1997, 99:315-324.
93. Hailman E., et al. Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein. J. Biol. Chem. 1996, 271:12172-12178.
94. Meyboom A., et al. Interaction of pulmonary surfactant protein A with phospholipid liposomes: a kinetic study on head group and fatty acid specificity. Biochim. Biophys. Acta 1999, 1441:23-35.
95. Chaby R., et al. Interactions between LPS and lung surfactant proteins. J. Endotoxin Res. 2005, 11:181-185.
96. Munford R.S., Hunter J.P. Acyloxyacyl hydrolase, a leukocyte enzyme that deacylates bacterial lipopolysaccharides, has phospholipase, lysophospholipase, diacylglycerollipase, and acyltransferase activities in vitro. J. Biol. Chem. 1992, 267:10116-10121.
97. Lemmon M.A. Membrane recognition by phospholipid-binding domains. Nat. Rev. Mol. Cell Biol. 2008, 9:99-111.
98. Eberhard D.A., Vandenberg S.R. Annexins I and II bind to lipid A: a possible role in the inhibition of endotoxins. Biochem. J. 1998, 330:67-72.
99. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
100. McGettrick A.F., O'Neill L.A. Localisation and trafficking of Toll-like receptors: an important mode of regulation. Curr. Opin. Immunol. 2010, 22:20-27.